Tyler E. Jacks founded T2 Biosystems, Inc. and Dragonfly Therapeutics, Inc. Presently, he holds the position of President & Director at Commonwealth Cancer Consortium, Inc. Dr. Jacks is also on the board of Amgen, Inc. and Thermo Fisher Scientific, Inc. and Professor at Massachusetts Institute of Technology.

In the past he was Director at David H. Koch Institute for Integrative Cancer Research and Chairman at National Cancer Institute.

He received an undergraduate degree from Harvard University and a doctorate from The University of California, San Francisco.